Patents Examined by Michael Pak
  • Antibody specifically binding to insulin-like growth factor-1
    Patent number: 9273144
    Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 1, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Hartmut Duefel, Michael Gerg, Frank Kowalewsky, Christian Scholz, Michael Schraeml
  • Anti-FGFR4 antibodies and methods of use
    Patent number: 9266955
    Abstract: The invention provides anti-FGFR4 antibodies and methods of using the same.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: February 23, 2016
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Luc Desnoyers, Dorothy French
  • Method for detecting novel FGFR4 mutant
    Patent number: 9267176
    Abstract: [Problem] An object of the present invention is to elucidate a novel genetic mutation which is a cause of cancer, and thereby, to provide a method for detecting the genetic mutation, or a protein which has the mutation, a method for detecting the presence of cancer in a subject, a method for diagnosing cancer in a subject, and a primer set, a probe and a detecting kit for the methods. [Means for Solution] A method for detecting a fibroblast growth factor receptor 4 (FGFR4) mutant in a subject, which comprises a step of detecting the presence of the mutation of glycine at position 183 in a FGFR4 tyrosine kinase domain to cysteine in a sample obtained from the subject.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 23, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Takashi Futami, Tatsuya Kawase, Nobuaki Shindou, Rumi Takeshita
  • Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
    Patent number: 9249207
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: February 2, 2016
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Marianna Zinovievna Kapitskaya
  • Glycoprotein hormone long-acting superagonists
    Patent number: 9249205
    Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: February 2, 2016
    Assignee: TROPHOGEN, INC.
    Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
  • Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
    Patent number: 9238690
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: January 19, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 9226964
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: January 5, 2016
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne King, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • Glycoprotein hormone long-acting superagonists
    Patent number: 9187545
    Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: November 17, 2015
    Assignee: Trophogen, Inc.
    Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
  • Anti-LGR5 antibodies and immunoconjugates
    Patent number: 9175089
    Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
  • Antibody against human prostaglandin Ereceptor EP4
    Patent number: 9175080
    Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: November 3, 2015
    Assignee: NB HEALTH LABORATORY CO., LTD.
    Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
  • Method for determining odor when using a self-tanning agent
    Patent number: 9170243
    Abstract: A method for evaluating an odor generated when using a self-tanning agent, wherein at least one compound selected from pyrazine compounds represented by the following general formula (1) is used as an indicator substance: wherein R1 represents a methyl group, an ethyl group or an acetyl group, and R2, R3 and R4 independently represent a hydrogen atom or a methyl group.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 27, 2015
    Assignee: Kao Corporation
    Inventors: Masayuki Yabuki, Miki Takahashi
  • Biological inhibitors of ROR1 capable of inducing cell death
    Patent number: 9150647
    Abstract: The invention relates to antibodies and siRNA molecules for inducing cell death by the specific binding of ROR1, domains thereof of nucleotide molecules encoding ROR1. There are also provided methods involving and uses of the antibodies and siRNA molecules of the invention.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: October 6, 2015
    Assignee: Kancera AB
    Inventors: Hakan Mellstedt, Ingrid Teige
  • Epitopes of the human PDGF receptor able to bind human auto-antibodies, antibodies and uses thereof
    Patent number: 9150634
    Abstract: The present invention refers to peptides comprised in the extracellular region of human PDGF receptor (hPDGFR) alpha, their use for detecting auto-antibodies anti-hPDGFR alpha and to a method for the diagnosis or the monitoring control for therapy of SSc. The present invention also refers to antibodies or recombinant or synthetic derivatives thereof able to recognize and bind to the above peptide and to their use in the treatment of SSc.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: October 6, 2015
    Inventors: Gianluca Moroncini, Ada Funaro, Armando Gabrielli, Vittorio Enrico Avvedimento, Silvia Svegliati Baroni, Mariarosaria Santillo, Roberto Paterno′
  • Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
    Patent number: 9146238
    Abstract: The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: September 29, 2015
    Assignee: The Johns Hopkins University
    Inventors: Jun Luo, George S. Bova, William Isaacs, Thomas Dunn, Rong Hu
  • Anti-EGFR antibodies and uses thereof
    Patent number: 9132192
    Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: September 15, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Daly, Gavin Thurston, Nicholas J. Papadopoulos
  • Fluorescein lactone ion indicators and their applications
    Patent number: 9097730
    Abstract: Fluorescent dyes useful for preparing fluorescent metal ion indicators, the fluorescent indicators themselves, and the use of the fluorescent indicators for the detection, discrimination and quantification of metal cations.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: August 4, 2015
    Assignee: AAT Bioquest, Inc.
    Inventors: Zhenjun Diwu, Jinfang Liao
  • Method for identifying compounds useful for treating and/or preventing disease-associated bone loss
    Patent number: 9091678
    Abstract: The present invention concerns a method for identifying a compound which inhibits the activation of RAC GTPase by DOCK5 protein comprising the steps of (i) coexpressing the DOCK5 and the RAC proteins in a cell, wherein said DOCK5 protein induces the conversion of inactive RAC, which inactive RAC is bound to GDP, to active RAC, which active RAC is bound to GTP, (ii) contacting or not said cell with said compound, (iii) determining the conversion of inactive RAC to active RAC in the presence or absence of said compound, and (iv) selecting the compound inhibiting the conversion of inactive RAC to active RAC. Said compound is useful for treating disease-associated bone loss.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: July 28, 2015
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventor: Anne Blangy
  • GDF15 as a differential marker for spondyloarthropathy
    Patent number: 9086419
    Abstract: In vitro methods for differential diagnosis of spondyloarthropathy are disclosed which involve determining the levels of GDF15 in biological samples.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: July 21, 2015
    Assignee: Universiteit Gent
    Inventors: Stijn Lambrecht, Dieter Deforce, Dirk Elewaut, August Verbruggen
  • HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction
    Patent number: 9075070
    Abstract: Disclosed are methods and kits for identifying modulators of the Keap1-Nrf2-ARE pathway. In particular, a high throughput fluorescent polarization assay is described that identifies small molecules that inhibit the binding of a fluorescently labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Also provided are probes that can be used in the described fluorescent polarization assay. The small molecules identified using the described assay are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: July 7, 2015
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Longqin Hu, Daigo Inoyama
  • Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof
    Patent number: 9074176
    Abstract: Disclosed are: a culture medium containing a specific growth factor and at least one phospholipid; a composition for preparation of the culture medium; a kit; and a method. A technique can be provided which uses a serum-free or low-serum culture medium and has a promoting effect on the proliferation of an animal cell comparable to the promoting effect obtained by the culture in a serum-containing culture medium.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: July 7, 2015
    Assignee: Two Cells Co., Ltd.
    Inventors: Yukio Kato, Jin Chang Shao, Yuki Katsura, Koichiro Tsuji